


# PRODUCT INFORMATION



## Ibiglustat

Item No. 32878

**CAS Registry No.:** 1401090-53-6  
**Formal Name:** N-[1-[2-(4-fluorophenyl)-4-thiazolyl]-1-methylethyl]-carbamic acid, (3S)-1-azabicyclo[2.2.2]oct-3-yl ester  
**Synonyms:** Genz-682452, GZ/SAR402671, Venglustat  
**MF:** C<sub>20</sub>H<sub>24</sub>FN<sub>3</sub>O<sub>2</sub>S  
**FW:** 389.5  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 293 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Ibiglustat is supplied as a crystalline solid. A stock solution may be made by dissolving the ibiglustat in the solvent of choice, which should be purged with an inert gas. Ibiglustat is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of ibiglustat in ethanol and DMF is approximately 30 mg/ml and approximately 25 mg/ml in DMSO.

Ibiglustat is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ibiglustat should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Ibiglustat has a solubility of approximately 0.12 mg/ml in a 1:7 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Ibiglustat is an inhibitor of glucosylceramide (GlcCer) synthase.<sup>1</sup> Dietary administration of ibiglustat (0.03% w/w) reduces globotriaosylceramide (Gb<sub>3</sub>) and lyso-Gb<sub>3</sub> accumulation in a variety of tissues, including the kidney, heart, and brain, in the *Gla*<sup>-/-</sup> mouse model of Fabry disease. It reduces the latency to paw withdrawal in the hot plate test in the same model, indicating reduced peripheral neuropathy. Ibiglustat (0.03% w/w in the diet) reduces gliosis, delays the onset of ataxia, and increases lifespan in the transgenic 4L;C\* mouse model of neuronopathic Gaucher disease.<sup>2</sup>

### References

1. Ashe, K.M., Budman, E., Bangari, D.S., *et al.* Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease. *Mol. Med.* **21**(1), 389-399 (2015).
2. Marshall, J., Sun, Y., Bangari, D.S., *et al.* CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease. *Mol. Ther.* **24**(6), 1019-1029 (2016).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/06/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
[WWW.CAYMANCHEM.COM](http://WWW.CAYMANCHEM.COM)